biophBiomedical PhotonicsBiomedical Photonics2413-9432Non-profit partnership for development of domestic photodynamic therapy and photodiagnosis10.24931/2413-9432-2023-13-1-19-25bioph-649Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВлияние состава комбинированных твердых липидных частиц с гефитинибом и фотосенсибилизатором на их размер, стабильность и цитотоксическую активностьEffect of the composition of combined solid lipid particles with gefitinib and a photosensitizer on their size, stability and cytotoxic activityНиколаеваЛ. Л.NikolaevaL. L.

Москва

Moscow

alima91@yandex.ruСанароваЕ. В.SanarovaE. V.

Москва

Moscow

КолпаксидиА. П.KolpaksidiA. P.

Москва

Moscow

ЩегловС. Д.ShcheglovS. D.

Москва

Moscow

РудаковаА. А.RudakovaA. A.

Москва

Moscow

БарышниковаМ. А.BaryshnikovaM. A.

Москва

Moscow

ЛанцоваА. В.LantsovaA. V.

Москва

Moscow

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Federation2024310720241321925Copyright © Николаева Л.Л., Санарова Е.В., Колпаксиди А.П., Щеглов С.Д., Рудакова А.А., Барышникова М.А., Ланцова А.В., 20242024Николаева Л.Л., Санарова Е.В., Колпаксиди А.П., Щеглов С.Д., Рудакова А.А., Барышникова М.А., Ланцова А.В.Nikolaeva L.L., Sanarova E.V., Kolpaksidi A.P., Shcheglov S.D., Rudakova A.A., Baryshnikova M.A., Lantsova A.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pdt-journal.com/jour/article/view/649

Создание комбинированных нанопрепаратов и их контролируемое высвобождение под воздействием фотоиндукции активно развивающаяся отрасль научных исследований. Данная работа посвящена разработке моделей твердых липидных наночастиц для известного противоопухолевого препарата – гефитиниба в комбинации с фотоиндицирующим агентом – фотосенсибилизатор из группы фталоцианинов. Наночастицы получали несколькими методами: горячей гомогенизацией со стеариновой кислотой, кунжутным маслом и твином 80 и путем одностадийного диспергирования с сополимерами молочной и гликолевой кислот и поливиниловым спиртом. В опытах in vitro при облучении частиц лазером в ближнем инфракрасном диапазоне (около 730 нм) было доказано преимущество применения комбинированных наночастиц с гефитинибоми фотосенсибилизатором по сравнению с монотерапией, при этом активность по показателю ИК50 была выше в 5,1-8,7 раз для гефитиниба и в 1,5-1,8 раз для фотосенсибилизатора.

The creation of combined nanomedicines and their controlled release under the influence of photoinduction is an actively developing branch of scientific research. This work is devoted to the development of models of solid lipid nanoparticles for a well-known antitumor drug – gefitinib in combination with a photoindicating agent – a photosensitizer from the phthalocyanine group. Nanoparticles were obtained by several methods: hot homogenization with stearic acid, sesame oil and Tween 80 and by one-step dispersion with copolymers of lactic and glycolic acids and polyvinyl alcohol. In vitro experiments when irradiating particles with a laser in the near-infrared range (about 730 nm) proved the advantage of using combined nanoparticles with gefitinib and a photosensitizer compared to monotherapy, while the activity in terms of IC50 was 5.1-8.7 times higher for gefitinib and 1.5-1.8 times for the photosensitizer.

твердые липидные наночастицыалюминия фталоцианингефитинибin vitroфотоиндуцированная активностьsolid lipid nanoparticlesaluminum phthalocyaninegefitinibin vitrophotoinduced activityReferencesJampilek J., Kralova K. Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy // Pharmaceutics. – 2022. – Vol. 14(12). – P. e2706. doi: 10.3390/pharmaceutics14122706.Jampilek J., Kralova K. Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy. Pharmaceutics, 2022, vol. 14(12), pp. e2706. doi: 10.3390/pharmaceutics14122706.Nadaf S.J., Killedar S.G., Kumbar V.M., Bhagwat D.A., Gurav S.S. Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer // International Journal of Pharmaceutics. – 2022. – Vol. 628. – P. e122287. doi: 10.1016/j.ijpharm.2022.122287.Nadaf S.J., Killedar S.G., Kumbar V.M., Bhagwat D.A., Gurav S.S. Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic eŠcacy against non-small cell lung cancer. International Journal of Pharmaceutics, 2022, vol. 628, pp.. e122287. doi: 10.1016/j.ijpharm.2022.122287.Kumar V., Khan I., Gupta U. Lipid-dendrimer nanohybrid system or dendrosomes: evidences of enhanced encapsulation, solubilization, cellular uptake and cytotoxicity of bortezomib //ApplNanosci. – 2020. – Vol. 10. – P. 4049-4062. doi: 10.1007/s13204-020-01515-7.Kumar V., Khan I., Gupta U. Lipid-dendrimer nanohybrid system or dendrosomes: evidences of enhanced encapsulation, solubilization, cellular uptake and cytotoxicity of bortezomib. ApplNanosci, 2020, vol. 10, pp.. 4049-4062. doi: 10.1007/s13204-020-01515-7.Gracias S., Ayyanar M., Peramaiyan G., Kalaskar M., Redasani V., Gurav N., Nadaf S., Deshpande M., Bhole R., Khan M.S., Chikhale R., Gurav S. Fabrication of chitosan nanocomposites loaded with biosynthetic metallic nanoparticles and their therapeutic investigation // Environmental Research. – 2023. – Vol. 234. – P. e116609. doi: 10.1016/j.envres.2023.116609.Gracias S., Ayyanar M., Peramaiyan G., Kalaskar M., Redasani V., Gurav N., Nadaf S., Deshpande M., Bhole R., Khan M.S., Chikhale R., Gurav S. Fabrication of chitosan nanocomposites loaded with biosynthetic metallic nanoparticles and their therapeutic investigation. Environmental Research, 2023, vol. 234, pp.. e116609. doi: 10.1016/j.envres.2023.116609.Meerovich I., Nichols M.G., Dash A.K. Low-intensity light-induced paclitaxel release from lipid-based nano-delivery systems // Journal of Drug Targeting. – 2019 – Vol. 27(9). – P. 971-983. doi: 10.1080/1061186X.2019.1571066.Meerovich I., Nichols M.G., Dash A.K. Low-intensity light-induced paclitaxel release from lipid-based nano-delivery systems. Journal of Drug Targeting, 2019, vol. 27(9), pp.. 971-983. doi: 10.1080/1061186X.2019.1571066.Yang T., Zhai J., Hu D., Yang R., Wang G., Li Y., Liang G. «Targeting Design» of Nanoparticles in Tumor Therapy // Pharmaceutics. – 2022. – Vol. 14(9). – P. 1919. doi: 10.3390/pharmaceutics14091919.Yang T., Zhai J., Hu D., Yang R., Wang G., Li Y., Liang G. «Targeting Design» of Nanoparticles in Tumor Therapy. Pharmaceutics, 2022, vol. 14(9), pp.. 1919. doi: 10.3390/pharmaceutics14091919.Makeen H.A., Mohan S., Al-Kasim M.A., Attafi I.M., Ahmed R.A., Syed N.K., Sultan M.H., Al-Bratty M., Alhazmi H.A., Safhi M.M., Ali R., Alam M.I. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro // Drug Delivery. – 2020. – Vol. 27(1). – P. 622-631. doi: 10.1080/10717544.2020.1754526.Makeen H.A., Mohan S., Al-Kasim M.A., Atta˝ I.M., Ahmed R.A., Syed N.K., Sultan M.H., Al-Bratty M., Alhazmi H.A., Safhi M.M., Ali R., Alam M.I. Ge˝tinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro. Drug Delivery, 2020, vol. 27(1), pp.. 622-631. doi: 10.1080/10717544.2020.1754526.Sapelnikov M.D., Nikolskaya E.D., Morozova N.B., Plotnikova E.A., Efremenko A.V., Panov A.V., Grin M.A., Yakubovskaya R.I. Development of the technology for obtaining PLGA and dipropoxybateriopurpurinimide-based nanoparticles. Evaluation of physicochemical and biological properties of the obtained delivery system // Biomedical Photonics. – 2019. – Vol. 8(1). – P. 4-17. doi:10.24931/2413-9432-2019-8-1-4-17.Sapelnikov M.D., Nikolskaya E.D., Morozova N.B., Plotnikova E.A., Efremenko A.V., Panov A.V., Grin M.A., Yakubovskaya R.I. Development of the technology for obtaining PLGA and dipropoxybateriopurpurinimide-based nanoparticles. Evaluation of physicochemical and biological properties of the obtained delivery system. Biomedical Photonics, 2019, vol. 8(1), pp.. 4-17. doi:10.24931/2413-9432-2019-8-1-4-17.Кедик С.А., Омельченко О.А., Суслов В.В., Шняк Е.А. Разработка способа получения налтрексона основания, инкапсулированного в полимерные микрочастицы // Разработка и регистрация лекарственных средств. – 2018. – Т. 7(1). – С. 32-35. Kedik S.A., Omelchenko O.A., Suslov V.V., Shnyak E.A. Development of a method for the preparation of the naltrexone base encapsulated in polymeric microparticles // Drug development & registration. – 2018. – Vol. 7(1). – P.32-35.Kedik S.A., Omelchenko O.A., Suslov V.V., Shnyak E.A. Development of a method for the preparation of the naltrexone base encapsulated in polymeric microparticles. Drug development & registration, 2018, vol. 7(1), pp.. 32-35.Kolpaksidi A. P., Dmitrieva M. V., Orlova O. L., Ektova L. V., Krasniuk I. I. Application of solid dispersion technology to obtain a model of injectable dosage form of indolocarbazole derivative// Drug development & registration. – 2022. – Vol. 11(4). – P.73-78. doi:10.33380/2305-2066-2022-11-4-73-78.Kolpaksidi A. P., Dmitrieva M. V., Orlova O. L., Ektova L. V., Krasniuk I. I. Application of solid dispersion technology to obtain a model of injectable dosage form of indolocarbazole derivative. Drug development & registration, 2022, vol. 11(4), pp..73-78. doi:10.33380/2305-2066-2022-11-4-73-78.Sanarova E.V., Lantsova A.V., Nikolaeva L.L., Oborotova N.A., Litvinenko Ya.E., Solov’eva N.L. Creation of a Model of a Complex Delivery Nanosystem Containing a Tyrosine Kinase Inhibitor and a Photosensitizer // Pharm Chem J. – 2023. – Vol. 57. – P. 1075-1079. doi:10.1007/s11094-023-02986-y.Sanarova E.V., Lantsova A.V., Nikolaeva L.L., Oborotova N.A., Litvinenko Ya.E., Solov’eva N.L. Creation of a Model of a Complex Delivery Nanosystem Containing a Tyrosine Kinase Inhibitor and a Photosensitizer. Pharm Chem J, 2023, vol. 57, pp.. 1075-1079. doi:10.1007/s11094-023-02986-y.Abo Qoura L., Morozova E.A., Koval V.S., Kulikova V.V., Spirina T.S., Demidova E.A., Demidkina T.V.,Pokrovsky V.S. Cytotoxic and antitumor properties of methionine γ-lyase conjugate in combination with S-alk(en) yl–L-cysteine sulfoxides // Russian Journal of Biotherapy. – 2022. – Vol. 21(4). – P. 62-70. doi:10.17650/1726-9784-2022-21-4-62-70.Abo Qoura L., Morozova E.A., Koval V.S., Kulikova V.V., Spirina T.S., Demidova E.A., Demidkina T.V.,Pokrovsky V.S. Cytotoxic and antitumor properties of methionine γ-lyase conjugate in combination with S-alk(en)yl–L-cysteine sulfoxides. Russian Journal of Biotherapy, 2022, vol. 21(4), pp.. 62-70. doi:10.17650/1726-9784-2022-21-4-62-70.Ionov N.S., Baryshnikova M.A., Bocharov E.V., Pogodin P.V., Lagunin A.A., Filimonov D.A., Karpova R.V., Kosorukov V.S., Stilidi I.S., Matveev V.B., Bocharova O.A., Poroikov V.V. Possibilities of in silico estimations for the development of pharmaceutical composition phytoladaptogene cytotoxic for bladder cancer cells // Biomed Khim. – 2021. – Vol. 67(3). – P. 278-288. doi:10.18097/PBMC20216703278.Ionov N.S., Baryshnikova M.A., Bocharov E.V., Pogodin P.V., Lagunin A.A., Filimonov D.A., Karpova R.V., Kosorukov V.S., Stilidi I.S., Matveev V.B., Bocharova O.A., Poroikov V.V. Possibilities of in silico estimations for the development of pharmaceutical composition phytoladaptogene cytotoxic for bladder cancer cells. Biomed Khim, 2021, vol. 67(3), pp.. 278-288. doi:10.18097/PBMC20216703278.

The authors declare that there are no conflicts of interest present.